Wigge & Partners is happy to have advised Saminvest on its 25 MEUR cornerstone investment into the first closing of Sound Bioventures, a newly established biotech fund with a focus on companies developing treatment options for rare diseases. Saminvest’s investment is part of its objective to increase available capital for Swedish start-ups.
Read more about the transaction here:
https://www.di.se/nyheter/ny-fond-ska-investera-i-lakemedel-for-ovanliga-sjukdomar/
https://www.realtid.se/sound-bioventures-reser-miljardfond-inriktad-pa-sallsynta-sjukdomar
Press releases:
https://www.saminvest.se/nyheter/2022/01/saminvest-investerar-i-sound-bioventures-life-science-fond/
